BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 36374798)

  • 1. Nanobubbles containing PD-L1 Ab and miR-424 mediated PD-L1 blockade, and its expression inhibition to enable and potentiate hepatocellular carcinoma immunotherapy in mice.
    Liu Y; Xie Q; Ma Y; Lin C; Li J; Hu B; Liu C; Zhao Y
    Int J Pharm; 2022 Dec; 629():122352. PubMed ID: 36374798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted Nanobubbles of PD-L1 mAb Combined with Doxorubicin as a Synergistic Tumor Repressor in Hepatocarcinoma.
    Chen Y; Luo X; Liu Y; Zou Y; Yang S; Liu C; Zhao Y
    Int J Nanomedicine; 2022; 17():3989-4008. PubMed ID: 36105615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanobubbles Containing sPD-1 and Ce6 Mediate Combination Immunotherapy and Suppress Hepatocellular Carcinoma in Mice.
    Tan Y; Yang S; Ma Y; Li J; Xie Q; Liu C; Zhao Y
    Int J Nanomedicine; 2021; 16():3241-3254. PubMed ID: 34007176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanobubble-mediated co-delivery of Ce6 and miR-195 for synergized sonodynamic and checkpoint blockade combination therapy with elicitation of robust immune response in hepatocellular carcinoma.
    Ma Y; Li J; Zhao Y; Hu B; Liu Y; Liu C
    Eur J Pharm Biopharm; 2022 Dec; 181():36-48. PubMed ID: 36307001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ultra-thin layered double hydroxide-mediated photothermal therapy combine with asynchronous blockade of PD-L1 and NR2F6 inhibit hepatocellular carcinoma.
    Lu YF; Zhou JP; Zhou QM; Yang XY; Wang XJ; Yu JN; Zhang JG; Du YZ; Yu RS
    J Nanobiotechnology; 2022 Jul; 20(1):351. PubMed ID: 35907841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted Ultrasound Nanobubbles Therapy for Prostate Cancer via Immuno-Sonodynamic Effect.
    Huang X; Chen Y; Zhong F; Gui B; Hu Y; Guo Y; Deng Q; Zhou Q
    Int J Nanomedicine; 2024; 19():2793-2806. PubMed ID: 38525011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 8. Nanobubble-based anti-hepatocellular carcinoma therapy combining immune check inhibitors and sonodynamic therapy.
    Liu Y; Yang S; Zhou Q; Zhou J; Li J; Ma Y; Hu B; Liu C; Zhao Y
    Nanoscale Adv; 2022 Nov; 4(22):4847-4862. PubMed ID: 36545394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
    Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
    Bai X; Zhou Y; Yokota Y; Matsumoto Y; Zhai B; Maarouf N; Hayashi H; Carlson R; Zhang S; Sousa A; Sun B; Ghanbari H; Dong X; Wands JR
    J Exp Clin Cancer Res; 2022 Apr; 41(1):132. PubMed ID: 35392977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isorhamnetin and anti-PD-L1 antibody dual-functional mesoporous silica nanoparticles improve tumor immune microenvironment and inhibit YY1-mediated tumor progression.
    Liu H; Han J; Lv Y; Zhao Z; Zheng S; Sun Y; Sun T
    J Nanobiotechnology; 2023 Jul; 21(1):208. PubMed ID: 37408047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemcitabine-facilitated modulation of the tumor microenvironment and PD-1/PD-L1 blockade generate a synergistic antitumor effect in a murine hepatocellular carcinoma model.
    Wang H; He X; Fang D; Wang X; Guan J; Shi ZW; Chen X
    Clin Res Hepatol Gastroenterol; 2022 Apr; 46(4):101853. PubMed ID: 34923183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
    Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemo-photodynamic therapy with light-triggered disassembly of theranostic nanoplatform in combination with checkpoint blockade for immunotherapy of hepatocellular carcinoma.
    Xu J; Zheng Q; Cheng X; Hu S; Zhang C; Zhou X; Sun P; Wang W; Su Z; Zou T; Song Z; Xia Y; Yi X; Gao Y
    J Nanobiotechnology; 2021 Oct; 19(1):355. PubMed ID: 34717654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer.
    Liu C; Liu R; Wang B; Lian J; Yao Y; Sun H; Zhang C; Fang L; Guan X; Shi J; Han S; Zhan F; Luo S; Yao Y; Zheng T; Zhang Y
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paeoniflorin inhibits hepatocellular carcinoma growth by reducing PD-L1 expression.
    Gao M; Zhang D; Jiang C; Jin Q; Zhang J
    Biomed Pharmacother; 2023 Oct; 166():115317. PubMed ID: 37597322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Efficient Combination Immunotherapy for Primary Liver Cancer by Harmonized Activation of Innate and Adaptive Immunity in Mice.
    Wen L; Xin B; Wu P; Lin CH; Peng C; Wang G; Lee J; Lu LF; Feng GS
    Hepatology; 2019 Jun; 69(6):2518-2532. PubMed ID: 30693544
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    He L; Xu K; Niu L; Lin L
    Pharm Biol; 2022 Dec; 60(1):1710-1720. PubMed ID: 36086826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
    Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX
    Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic anti-tumor effect of anti-PD-L1 antibody cationic microbubbles for delivery of the miR-34a gene combined with ultrasound on cervical carcinoma.
    Liu Y; Jiang J; Liu C; Zhao W; Ma Y; Zheng Z; Zhou Q; Zhao Y
    Am J Transl Res; 2021; 13(3):988-1005. PubMed ID: 33841635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.